Published:
January 13, 2022
Last Updated:
January 13, 2022
Services:
CPG More...
Priorities:
Consumer Health and Wellness
Topics:
Aging Technologies | Biosensors More...
Activities:
Policy
Further Reading
Deep Genomics raises $180 million Series C for AI-enabled RNA therapeutic discovery
News Commentary | August 17, 2021
The company develops an AI platform for the discovery of RNA therapies, and it plans to use the funds to further advance its preclinical pipeline. Deep genomics currently researches central nervous system and metabolic diseases. The utilization of AI could potentially develop novel therapeutics in ... Not part of subscription
China approves OrgiMed's NGS-based genomic alteration tumor test
News Commentary | September 08, 2021
The test, which was made in collaboration with Bayer, was developed to detect rare NTRK gene fusions in both children and adults. It is a companion diagnostic to a gene inhibitor therapy that specifically targets NTRK cancers. Clients should note how genomic sequencing can be utilized for diagnostic... Not part of subscription
NHS launches world's largest liquid biopsy trial, which could potentially detect 50 types of cancer
News Commentary | September 17, 2021
NHS will use GRAIL's Galleri test in this study, which aims to recruit 140,000 volunteers in eight areas of England. Besides being touted as the world's first and largest clinical trial of its kind, the more important significance of this study is that it is being spearheaded by one of the largest ... Not part of subscription
by Brian O'Shea
The U.S. FDA has given 23andMe approval to expand its genetic health risk report by screening for a G84E mutation in the HOXB13 gene. This mutation has been linked to an increase in prostate cancer. A recent study showed that males with a G84E gene mutation were 66% more likely to have prostate cancer than their noncarrier peers. 23andMe's test was shown to be 99% effective in finding this biomarker. 23andMe adds this test to two other FDA-approved cancer screenings, one for breast cancer and one for colorectal cancer. It remains the only company with direct-to-consumer screening products. Clients in both the biomarkers and genomics spaces should take note of 23andMe's success in this field and look for partnership opportunities.
For the original news article, click here .